🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Immunoglobulin A Nephropathy

A Study of SHR-2173 in Participants With Primary IgA Nephropathy NCT07354932Phase 22 sites📍 Guangzhou📍 Shanghai Guangdong Hengrui Pharmaceutical Co., Ltd · Tests: SHR-2173 injection, SHR-2173 injection, SHR-2173 injection, Placebo A Study of JADE101 in Participants With Immunoglobulin A Nephropathy NCT07541287Phase 220 sites📍 Chula Vista📍 Arvada📍 Denver Jade Biosciences, Inc. · Tests: JADE101 Correlation of Microbiome and Metabonomics With IgA Nephropathy NCT05190848n/a5 sites📍 Guangzhou📍 Guangzhou📍 Guangzhou Guangdong Provincial People's Hospital A Phase 1 Study of CLYM116 in Normal Healthy Volunteers NCT07248865Phase 11 site📍 Brisbane Climb Bio, Inc. · Tests: CLYM116, Placebo A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases. NCT07203404EARLY Phase 11 site📍 Shanghai Nanjing Bioheng Biotech Co., Ltd. · Tests: RD06-05 CART Cell Injection IgA Nephropathy Biomarkers Evaluation Study (INTEREST) NCT02954419n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: No intervention China Kidney Patient Trials Network NCT05036850n/a1 site📍 Beijing George (Beijing) Clinical Research Co. Ltd. A Phase 1b/2 Study of the Safety and Efficacy of the Monoclonal Antibody OM-RCA-01 in Patients With Metastatic Tumors Expressing Fibroblast Growth Factor Receptor 1 NCT07292168Phase 1, Phase 25 sites📍 Kazan'📍 Krasnoyarsk📍 Moscow Kidney Cancer Research Bureau · Tests: humanized monoclonal anti-FGFR1 antibody OM-RCA-01 A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy NCT05668403Phase 16 sites📍 Zhengzhou📍 Shijiazhuang📍 Hangzhou Shanghai Jiaolian Drug Research and Development Co., Ltd · Tests: B007, B007, B007 The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA) NCT04858724n/a1 site📍 Shanghai Ruijin Hospital Study of BHV-1400 in IgA Nephropathy NCT07054684Phase 115 sites📍 Farmington📍 Miami Lakes📍 Miami Lakes Biohaven Therapeutics Ltd. · Tests: BHV-1400 CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease NCT07305116Phase 11 site📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… · Tests: UCAR T-cell IgA Nephropathy Registration Initiative of High Quality (INSIGHT) NCT03001947n/a1 site📍 Guangzhou Sun Yat-sen University · Tests: No intervention A Mobile App-Based Study to Evaluate Disease Burden and Treatment Patterns in Immunoglobulin A Nephropathy (IgAN) in the US NCT06952426n/a1 site📍 Boston Novartis Pharmaceuticals · Tests: No intervention, Other treatment, Iptacopan, Atrasentan M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors NCT07166601Phase 15 sites📍 New Haven📍 New York📍 San Antonio EMD Serono Research & Development Institute, Inc. · Tests: M0324, M0324, Pembrolizumab, mFOLFIRINOX A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy NCT04557462Phase 3161 sites📍 Glendale📍 San Diego📍 San Dimas Novartis Pharmaceuticals · Tests: LNP023 Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis NCT07010250n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma NCT07594106Phase 1, Phase 26 sites📍 Goodyear📍 Duarte📍 Tampa Regeneron Pharmaceuticals · Tests: REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD) NCT07619820Phase 11 site📍 Beijing CSL Behring · Tests: CSL300, Placebo Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma NCT05738694Phase 38 sites📍 Beijing📍 Beijing📍 Guangzhou ZHOU FANGJIAN · Tests: Axitinib plus Toripalimab, nephrectomy Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected Proteinuric Glomerular Diseases NCT07614477Phase 22 sites📍 Beijing📍 Tianjin Everest Medicines (China) Co.,Ltd. · Tests: EVER001 A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA Nephropathy NCT07616700Phase 22 sites📍 Beijing📍 Beijing Haisco Pharmaceutical Group Co., Ltd. · Tests: HSK39297 200mgQD, HSK39297 300mgQD Chinese Adults With Kidney Disease NCT07522099Phase 29 sites📍 Shenzhen📍 Guiyang📍 Zhengzhou ADARx Pharmaceuticals, Inc. · Tests: ADX-038, Telitacicept A Study of the Safety and Activity of Sparsentan for the Treatment of Patients With Immunoglobulin A Nephropathy NCT04663204Phase 26 sites📍 Cambridge📍 Salford📍 Edinburgh University of Leicester · Tests: Sparsentan Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford NCT01793168n/a2 sites📍 Sioux Falls📍 Sydney Sanford Health A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy. NCT07375758Phase 1, Phase 21 site📍 Beijing Beijing Mabworks Biotech Co., Ltd. · Tests: MIL116, Matching Placebo RESistance of IgA Nephropathy to Conventional and Newly-approved Therapies: an Observational, Real-life Study (RESIGAN) NCT06926244n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease NCT06308978Phase 121 sites📍 Beverly Hills📍 Fullerton📍 Irvine Fate Therapeutics · Tests: FT819, Fludarabine, Cyclophosphamide, Bendamustine Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease NCT07507201EARLY Phase 11 site📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… · Tests: UCAR T-cell KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis NCT03929887n/a6 sites📍 Chuncheon📍 Daegu📍 Seoul Seoul National University Hospital · Tests: Kidney Biopsy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy